Radiotherapy & Oncology
Volume 94, Issue 2 , Pages 173-180, February 2010

From point A to the sculpted pear: MR image guidance significantly improves tumour dose and sparing of organs at risk in brachytherapy of cervical cancer

Received 4 November 2009; received in revised form 4 January 2010; accepted 7 January 2010. published online 08 February 2010.

Abstract 

Background and purpose

Brachytherapy in locally advanced cervical cancer is still widely based on 2D standard dose planning, although 3D image guidance is available. The purpose of this study was to compare point doses to 3D dose volume parameters for tumour and organs at risk (OARs), and to evaluate the improvement of dose parameters with MR image guided adaptive brachytherapy (IGABT).

Material and methods

MRI-based IGABT was performed in 72 consecutive patients. HR-CTV, IR-CTV, bladder, rectum and sigmoid were contoured according to GEC-ESTRO recommendations. BT standard dose planning was compared to MRI-based dose optimisation.

Results

HR-CTV dose (D90) was highly variable in standard plans with point A dose prescription. In small tumours (<31cc) HR-CTV was well covered by standard plans in 94% of patients, while OAR constraints were exceeded in 72% of patients. Optimisation decreased violation of OAR constraints to only 6% of patients while maintaining excellent target coverage. In large tumours (>31cc) the dose optimisation improved the HR-CTV D90 by a mean of 7Gy resulting in full coverage in 72% of patients as compared to 25% for standard plans, even while reducing violation of OAR constraints.

Conclusion

Point A dose is a poor surrogate of HR-CTV dose, and the use of 3D image-based dose planning is encouraged. MRI-based IGABT significantly improves target coverage and OAR dose.

Keywords: Brachytherapy, Image guidance, Cervical cancer, DVH parameters

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0167-8140(10)00020-4

doi:10.1016/j.radonc.2010.01.001

Radiotherapy & Oncology
Volume 94, Issue 2 , Pages 173-180, February 2010